| P50 | author | Lauren S Sherman | Q59695118 |
| P2093 | author name string | Pranela Rameshwar | |
| | Katherine Liu | |
| | Alexander Aleynik | |
| | Yuriy A Gubenko | |
| | Kevin M Gernavage | |
| | Yasmine Sh Mourad | |
| P2860 | cites work | miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells | Q21245271 |
| | Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides | Q22242269 |
| | New insights into brain BDNF function in normal aging and Alzheimer disease | Q22252335 |
| | The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo | Q24657924 |
| | Particle-mediated delivery of cytokines for immunotherapy | Q26997993 |
| | Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. | Q27824850 |
| | A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA | Q27860813 |
| | Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II) | Q28175138 |
| | Exosomes: a common pathway for a specialized function | Q28254986 |
| | Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier | Q28257034 |
| | Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7 | Q28303603 |
| | Diversity of raft-like domains in late endosomes | Q28469178 |
| | Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease | Q29547175 |
| | Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein | Q29547803 |
| | The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors | Q30435946 |
| | Combining microbubbles and ultrasound for drug delivery to brain tumors: current progress and overview | Q30442623 |
| | Measuring outcome in traumatic brain injury treatment trials: recommendations from the traumatic brain injury clinical trials network | Q30496591 |
| | Development of neuropeptide drugs that cross the blood-brain barrier | Q33569277 |
| | Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial | Q33605719 |
| | Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. | Q33819663 |
| | microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network. | Q33883240 |
| | Drug delivery to brain via the blood-brain barrier | Q33963752 |
| | Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound | Q34003611 |
| | Global changes of mRNA expression reveals an increased activity of the interferon-induced signal transducer and activator of transcription (STAT) pathway by repression of miR-221/222 in glioblastoma U251 cells | Q34112784 |
| | Isoflurane anesthesia induced persistent, progressive memory impairment, caused a loss of neural stem cells, and reduced neurogenesis in young, but not adult, rodents. | Q34171102 |
| | Stem cells as therapeutic vehicles for the treatment of high-grade gliomas | Q34240433 |
| | Mesenchymal stem cells in bone development, bone repair, and skeletal regeneration therapy. | Q34319936 |
| | Selectin-mediated recruitment of bone marrow stromal cells in the postischemic cerebral microvasculature | Q34590239 |
| | Current status of local therapy in malignant gliomas--a clinical review of three selected approaches. | Q34733023 |
| | Getting into the brain: approaches to enhance brain drug delivery | Q34897833 |
| | Exosomes as immunotheranostic nanoparticles. | Q35174460 |
| | Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity | Q39776996 |
| | Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model | Q39869090 |
| | Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal | Q39916475 |
| | Focused ultrasound microbubble destruction-mediated changes in blood-brain barrier permeability assessed by contrast-enhanced magnetic resonance imaging | Q39935746 |
| | Bystander killing of malignant glioma by bone marrow-derived tumor-infiltrating progenitor cells expressing a suicide gene | Q40141485 |
| | Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. | Q40195961 |
| | Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix | Q40617695 |
| | Separation and characterization of late endosomal membrane domains | Q40725060 |
| | Gene therapy of multiple sclerosis using interferon β-secreting human bone marrow mesenchymal stem cells | Q40726859 |
| | Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. | Q42218017 |
| | Use of memantine to treat Alzheimer's disease | Q42880780 |
| | Mesenchymal stem cells enhance the engraftment and myelinating ability of allogeneic oligodendrocyte progenitors in dysmyelinated mice | Q43636678 |
| | Brain and spinal cord distribution of biphalin: correlation with opioid receptor density and mechanism of CNS entry. | Q44346739 |
| | Structural changes in the rat brain after carotid infusions of hyperosmolar solutions: a light microscopic and immunohistochemical study | Q44572388 |
| | Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease | Q45298203 |
| | Human adipose tissue-derived mesenchymal stem cells: characteristics and therapeutic potential as cellular vehicles for prodrug gene therapy against brainstem gliomas | Q45870836 |
| | Exosomes are released by cultured cortical neurones. | Q46918951 |
| | Effects of transcranial ultrasound and intravenous microbubbles on blood brain barrier permeability in a large animal model | Q47406084 |
| | Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling | Q47620825 |
| | Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcome | Q48198558 |
| | Molecular Trojan horses for blood-brain barrier drug delivery. | Q48306206 |
| | Dual response of BDNF to sublethal concentrations of beta-amyloid peptides in cultured cortical neurons. | Q48436062 |
| | Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease | Q48820847 |
| | Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas | Q48926056 |
| | Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. | Q50767537 |
| | Neural differentiation of brain-derived neurotrophic factor-expressing human umbilical cord blood-derived mesenchymal stem cells in culture via TrkB-mediated ERK and β-catenin phosphorylation and following transplantation into the developing brain. | Q53435365 |
| | Mesenchymal Stem Cell-Conditioned Medium Triggers Neuroinflammation and Reactive Species Generation in Organotypic Cultures of Rat Hippocampus | Q60349719 |
| | Mesenchymal Stem Cell-Mediated Immunosuppression Occurs via Concerted Action of Chemokines and Nitric Oxide | Q61645540 |
| | In search of the in vivo identity of mesenchymal stem cells | Q81485769 |
| | microRNAs, Gap Junctional Intercellular Communication and Mesenchymal Stem Cells in Breast Cancer Metastasis | Q35185340 |
| | The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier | Q35585191 |
| | Lipids as targeting signals: lipid rafts and intracellular trafficking. | Q35696773 |
| | Identification and proteomic profiling of exosomes in human cerebrospinal fluid | Q35744824 |
| | Concise review: Mesenchymal stem cell tumor-homing: detection methods in disease model systems | Q36089997 |
| | Intravenous mesenchymal stem cells improve survival and motor function in experimental amyotrophic lateral sclerosis | Q36130979 |
| | Brain meets body: the blood-brain barrier as an endocrine interface | Q36177451 |
| | The art of gene therapy for glioma: a review of the challenging road to the bedside | Q36527593 |
| | Mesenchymal stem cells deliver synthetic microRNA mimics to glioma cells and glioma stem cells and inhibit their cell migration and self-renewal | Q37016591 |
| | Remyelination of the spinal cord following intravenous delivery of bone marrow cells | Q37020042 |
| | Therapeutic nanomedicine for brain cancer | Q37338427 |
| | Stem cell-based cell therapy in neurological diseases: a review | Q37419268 |
| | Biological functionalization of drug delivery carriers to bypass size restrictions of receptor-mediated endocytosis independently from receptor targeting | Q37514889 |
| | Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases | Q37576225 |
| | Oncogenic EGFR signaling networks in glioma | Q37593841 |
| | Tumor-derived exosomes: A message delivery system for tumor progression. | Q37716749 |
| | Intrathecal therapy for cancer and non-cancer pain. | Q37876696 |
| | MicroRNAs as regulators of neural stem cell-related pathways in glioblastoma multiforme | Q37897499 |
| | Targeting strategies for multifunctional nanoparticles in cancer imaging and therapy | Q37978315 |
| | Current thoughts on the therapeutic potential of stem cell | Q38011631 |
| | Drug delivery to the brain via the blood-brain barrier: a review of the literature and some recent patent disclosures | Q38029666 |
| | Stem cell based glioblastoma gene therapy | Q38031961 |
| | Mesenchymal stem cells as therapeutic agents and potential targeted gene delivery vehicle for brain diseases | Q38033935 |
| | Mesenchymal stem cells in drug/gene delivery: implications for cell therapy. | Q38040409 |
| | Receptor-mediated endocytosis and brain delivery of therapeutic biologics | Q38120524 |
| | From blood to the brain: can systemically transplanted mesenchymal stem cells cross the blood-brain barrier? | Q38133556 |
| | Drug and cell encapsulation: alternative delivery options for the treatment of malignant brain tumors. | Q38184764 |
| | Recent advances in delivery through the blood-brain barrier | Q38200122 |
| | MiRNA-451 plays a role as tumor suppressor in human glioma cells | Q38341125 |
| | Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. | Q38593312 |
| | Tumor-targeted enzyme/prodrug therapy mediates long-term disease-free survival of mice bearing disseminated neuroblastoma | Q38961512 |
| | Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma | Q39512141 |
| | miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-β | Q39646428 |
| | Human stem cells expressing novel TSP-1 variant have anti-angiogenic effect on brain tumors. | Q39725116 |
| | Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status | Q39756064 |
| P304 | page(s) | 24 | |
| P577 | publication date | 2014-07-19 | |
| P1433 | published in | Clinical and translational medicine | Q27724586 |
| P1476 | title | Stem cell delivery of therapies for brain disorders | |
| P478 | volume | 3 | |